Lysyl oxidase-like 2 (LOXL2) and E47 EMT factor: Novel partners in E-cadherin repression and early metastasis colonization

Oncogene

Volumn 34, Issue 8, 2015, Pages 951-964

  Canesin, G ^a,e   Cuevas, E P ^a   Santos, V ^a   Lopez Menendez C ^a   Moreno Bueno, G ^a,b   Huang, Y ^c   Csiszar, K ^d   Portillo, F ^a   Peinado, H ^c   Lyden, D ^c   Cano, A ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b MD ANDERSON CANCER CENTER   (Spain)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF HAWAII   (United States)

^e LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; LOXL2 PROTEIN, MOUSE; OXIDOREDUCTASE; TRANSCRIPTION FACTOR 3;

ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; C57BL MOUSE; CELL CULTURE; CELL MOTION; DOG; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HEK293 CELL LINE; HUMAN; LUNG TUMOR; METASTASIS; MOUSE; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; SECONDARY;

AMINO ACID OXIDOREDUCTASES; ANIMALS; BREAST NEOPLASMS; CADHERINS; CELL MOVEMENT; CELLS, CULTURED; DOGS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HEK293 CELLS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM METASTASIS; TRANSCRIPTION FACTOR 3;

EID: 84895914531     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.23     Document Type: Article

References (43)

1. Thiery JP, Acloque H, Huang R, Nieto MA. Epithelial-mesenchymal transitions in development end disease. Cell 2009; 139: 871-890.
2. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-273.
3. Nieto MA. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol 2011; 27: 347-376.
4. Moreno-Bueno G, Portillo F, Cano A. Transcriptional regulation of cell polarity in EMT and cancer. Oncogene 2008; 27: 6958-6969.
5. Peinado H, Olmeda D, Snail Cano A. Zeb and bHLH factors in tumor progression: an alliance against the epithelial phenotype Nat Rev Cancer 2007; 7: 415-428.
6. Nieto MA, Cano A. The epithelial-mesenchymal transition under control: Global programs to regulate epithelial plasticity. Sem Cancer Biol 2012; 22: 361-368.
7. Perez-Moreno MA, Locascio A, Rodrigo I, Dhondt G, Portillo F, Nieto MA et al. A new role for E12/E47 in the repression of E-cadherin expression and epithelial mesenchymal transitions. J Biol Chem 2001; 276: 27424-27431.
8. Peinado H, Marin F, Cubillo E, Stark HJ, Fusenig N, Nieto MA et al. Snail and E47 repressors of E-cadherin induce distinct invasive and angiogenic properties in vivo. J Cell Sci 2004; 117: 2827-2839.
9. Cubillo M, Diaz-Lopez A, Cuevas EP, Moreno-Bueno G, Peinado H, Montes A et al. E47 and id1 interplay in epithelial-mesenchymal transition. PLoS One 2013; 8: e59948.
10. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013; 13: 97-110.
11. Peinado H, Iglesias-de la Cruz MC, Olmeda D, Csiszar K, Fong KS, Vega S et al. A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression. EMBO J 2005; 24: 3446-3458.
12. Peinado H, Moreno-Bueno G, Hardisson D, Pérez-Gómez E, Santos V, Mendiola M et al. Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas. Cancer Res 2008; 68: 4541-4550.
13. Moreno-Bueno G, Salvador F, Martín A, Floristán A, Cuevas EP, Santos V et al. Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas. EMBO Mol Med 2011; 3: 528-544.
14. Csiszar K. Lysyl oxidases: a novel multifunctional amine oxidase family. Prog Nucleic Acid Res Mol Biol 2001; 70: 1-32.
15. Mäki JM, Räsänen J, Tikkanen H, Sormunen R, Mäkikallio K, Kivirikko KI et al. Inactivation of the lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice. Circulation 2002; 106: 2503-2509.
16. Liu X, Zhao Y, Gao J, Pawlyk B, Starcher B, Spencer JA et al. Elastic fiber homeostasis requires lysyl oxidase-like 1 protein. Nat Genet 2004; 36: 178-182.
17. Barker HE, Cox TR, Erler JT. The rationale for targeting the LOX family in cancer. Nat Rev Cancer 2012; 12: 540-552.
18. Cano A, Santamaria PG, Moreno-Bueno G. LOXL2 in epithelial cell plasticity and tumor progression. Future Oncol 2012; 8: 1095-1108.
19. Barker HE, Chang J, Cox TR, Lang G, Bird D, Nicolau M et al. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. Cancer Res 2011; 71: 1561-1572.
20. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer 2009; 9: 285-293.
21. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature 2005; 438: 820-827.
22. Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for premetastatic niche formation: Old sayings and new thoughts. Semin Cancer Biol 2011; 21: 139-146.
23. Erler JT, Bennewith KL, Nicolau M, Dornhöfer N, Kong C, Le QT et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006; 440: 1222-1226.
24. Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009; 15: 35-44.
25. Wong CC, Gilkes DM, Zhang H, Chen J, Wei H, Chaturvedi P et al. Hypoxiainducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci USA 2011; 108: 16369-16374.
26. Cuevas EP, Moreno-Bueno G, Canesin G, Santos V, Portillo F, Cano A. LOXL2 catalytically inactive mutants mediate epithelial-to-mesenchymal transition. Biology Open 2014; 3: 129-137.
27. Massari ME, Jennings PA, Murre C. The AD1 transactivation domain of E2A contains a highly conserved helix which is required for its activity in both Saccharomyces cerevisiae and mammalian cells. Mol Cell Biol 1996; 16: 121-129.
28. Ewens A, Mihich E, Ehrke MJ. Distant metastasis from subcutaneously grown E0771 medullary breast adenocarcinoma. Anticancer Res 2005; 25: 3905-3915.
29. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 2006; 8: 1369-1375.
30. Bosiljcic M, Hamilton MJ, Banath JP, LePard NE, McDougal DC, Jia JX et al. Myeloid suppressor cells regulate the lung environment-Letter. Cancer Res 2011; 71: 5050-5051.
31. Hiratsuka S, Watanabe A, Sakurai Y, Akashi-Takamura S, Ishibashi S, Miyake K et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a premetastatic phase. Nat Cell Biol 2008; 10: 1349-1355.
32. Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med 2011; 17: 867-874.
33. Peng L, Ran YL, Hu H, Yu L, Liu Q, Zhou Z et al. Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway. Carcinogenesis 2009; 30: 1660-1669.
34. Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010; 16: 1009-1017.
35. Ocanã OH, Córcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx. Cancer Cell 2012; 22: 709-724.
36. Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012; 22: 725-736.
37. Gao D, Joshi N, Choi H, Ryu S, Hahn M, Catena R et al. Myeloid progenitor cells in the premetastatic lung promote metastasis by inducing mesenchymal to epithelial transition. Cancer Res 2012; 72: 1384-1394.
38. Ye XZ, Yu SC, Bian XW. Contribution of myeloid-derived suppressor cells to tumorinduced immune suppression, angiogenesis, invasion and metastasis. J Genet Genomics 2010; 37: 423-430.
39. Sceneay J, Chow MT, Chen A, Halse HM, Wong CS, Andrews DM et al. Primary Tumor Hypoxia Recruits CD11b+/Ly6Cmed/Ly6G+ Immune Suppressor Cells and Compromises NK Cell Cytotoxicity in the Premetastatic Niche. Cancer Res 2012; 72: 3906-3911.
40. Fogelgren B, Polgár N, Szauter KM, Ujfaludi Z, Laczkó R, Fong KS et al. Cellular fibronectin binds to lysyl oxidase with high affinity and is critical for its proteolytic activation. J Biol Chem 2005; 280: 24690-24697.
41. Cox TR, Bird D, Baker AM, Barker HE, Ho MW, Lang G et al. LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Res 2013; 73: 1721-1732.
42. Moreno-Bueno G, Peinado H, Molina P, Olmeda D, Cubillo E, Santos V et al. The morphological and molecular features of the epithelial-to-mesenchymal transition. Nat Protoc 2009; 4: 1591-1613.
43. Peinado H, Alekovi M, Lavotshkin S, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M et al. Melanoma-derived exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through upregulation of the MET oncoprotein. Nat Med 2012; 18: 883-891.